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Tick-borne encephalitis (TBE) is a debilitating and often
fatal neuroinfection caused by RNA viruses belonging to
the Flaviviridae family. Licensed inactivated TBE vaccines
are currently available in Europe and Russia, however,
three doses of vaccine are required for primary immuniza-
tion, and subsequent booster vaccinations every 3 years
are needed to maintain protective immunity. Despite
immunization of populations living in endemic areas
using inactivated TBE vaccines, TBE remains a pressing
public health problem. A less expensive live TBE vaccine
that induces more durable immunity is needed.
Based on previous preclinical evaluation in mice and
monkeys, the chimeric TBEV/DEN4Δ30 virus, carrying the
prM and E protein genes from a highly virulent Far Eastern
strain of tick-borne encephalitis virus (TBEV) on the back-
bone of a non-neuroinvasive dengue type 4 virus (DEN4),
has been identified as a promising live attenuated virus
vaccine candidate against disease caused by TBEV. How-
ever, prior to use of this vaccine candidate in humans, its
neurovirulence in non-human primates needed to be
evaluated.
In the present study, we compared the neuropathogenesis
of the chimeric TBEV/DEN4Δ30 virus, Langat virus
(LGTV), a former live TBEV vaccine, and yellow fever 17D
virus vaccine (YF 17D) in rhesus monkeys inoculated
intracerebrally. TBEV/DEN4Δ30 and YF 17D demon-
strated remarkably similar spatiotemporal profiles of
virus replication and virus-associated histopathology in
the CNS that were high in cerebral hemispheres but pro-
gressively decreased toward the spinal cord. In contrast,
the neurovirulence of LGTV exhibited the reverse profile
progressing from the site of inoculation toward the cere-
bellum and spinal cord. Analysis of the spatiotemporal
distribution of viral antigens in the CNS of monkeys
revealed a prominent neurotropism associated with all
three attenuated viruses. Nevertheless, TBEV/DEN4Δ30
virus exhibited higher neurovirulence in monkeys com-
pared to either LGTV or YF 17D, suggesting insufficient
attenuation.
Our results provide insight into the neuropathogenesis
beyond the most often analyzed time point on day 30
post-inoculation and demonstrate that attenuated flavivi-
ruses can be more reliably discriminated by their his-
topathological profile at earlier time points, such as day
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14 to 21. These findings and our modified methodology
of histopathological evaluation of neurovirulence associ-
ated with attenuated flaviviruses may guide the design of
safe vaccines against neurotropic flaviviruses.
We are currently performing a computerized morphomet-
ric analysis of the cellular inflammatory responses within
the CNS of monkeys to investigate their role in the neu-
ropathogenesis and contribution to the outcome of neu-
roinfection. Results of these studies will be presented.Page 2 of 2
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